Portal vein thrombosis is associated with an increased risk of bone fractures.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
02
2022
accepted:
10
04
2022
entrez:
22
4
2022
pubmed:
23
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Portal vein thrombosis (PVT) is a rare but severe disease that often leads to portal hypertension-related complications. It is well-known that patients with portal hypertension associated with liver cirrhosis are at increased risk for bone fractures, however data on the impact of PVT on fracture risk are lacking. This study aimed to explore the impact of PVT on the incidence of bone fractures in a large German primary care cohort. Patients with PVT were extensively matched to non-PVT individuals in a 1:5 ratio. The primary outcome of the study was the incidence of any bone fracture. This study included 596 patients with PVT and 2,980 non-PVT individuals. During five years of follow-up, the cumulative incidence of bone fractures was significantly higher in PVT patients (n = 87, 13.6%) than in those without PVT (n = 186, 6.7%) (p<0.001). In Cox-regression analyses, PVT was positively associated with bone fractures (HR: 2.16; 95% CI: 1.59-2.93). This association was stronger in women (HR: 2.55; 95% CI: 1.65-3.95) than in men (HR: 1.87; 95% CI: 1.22-2.87). The strongest association was observed in the age group 51-60 years (HR: 2.50, 95% CI: 1.40-4.47). The association between PVT and bone fractures was maintained in subgroup analyses of patients with (HR: 2.03, 95% CI: 1.13-3.63) and without liver cirrhosis (HR: 1.82, 95% CI: 1.28-2.58). PVT is independently associated with a higher incidence of bone fractures. Patients with PVT should be critically evaluated for fracture risk and preventive measures should be considered.
Sections du résumé
BACKGROUND
Portal vein thrombosis (PVT) is a rare but severe disease that often leads to portal hypertension-related complications. It is well-known that patients with portal hypertension associated with liver cirrhosis are at increased risk for bone fractures, however data on the impact of PVT on fracture risk are lacking.
AIMS
This study aimed to explore the impact of PVT on the incidence of bone fractures in a large German primary care cohort.
METHODS
Patients with PVT were extensively matched to non-PVT individuals in a 1:5 ratio. The primary outcome of the study was the incidence of any bone fracture.
RESULTS
This study included 596 patients with PVT and 2,980 non-PVT individuals. During five years of follow-up, the cumulative incidence of bone fractures was significantly higher in PVT patients (n = 87, 13.6%) than in those without PVT (n = 186, 6.7%) (p<0.001). In Cox-regression analyses, PVT was positively associated with bone fractures (HR: 2.16; 95% CI: 1.59-2.93). This association was stronger in women (HR: 2.55; 95% CI: 1.65-3.95) than in men (HR: 1.87; 95% CI: 1.22-2.87). The strongest association was observed in the age group 51-60 years (HR: 2.50, 95% CI: 1.40-4.47). The association between PVT and bone fractures was maintained in subgroup analyses of patients with (HR: 2.03, 95% CI: 1.13-3.63) and without liver cirrhosis (HR: 1.82, 95% CI: 1.28-2.58).
CONCLUSIONS
PVT is independently associated with a higher incidence of bone fractures. Patients with PVT should be critically evaluated for fracture risk and preventive measures should be considered.
Identifiants
pubmed: 35452487
doi: 10.1371/journal.pone.0267535
pii: PONE-D-22-04652
pmc: PMC9032344
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0267535Déclaration de conflit d'intérêts
Krael Kostev is Scientific Principal-Epidemiology Research at IMS Health (IQVIA) in Frankfurt (Germany). However, IQVIA has no influence on the content or publication of this manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors disclose no potential financial or non-financial conflicts of interest.
Références
BMJ Open. 2017 Oct 08;7(10):e017342
pubmed: 28993387
CMAJ. 2009 Sep 1;181(5):265-71
pubmed: 19654194
Clin Liver Dis (Hoboken). 2014 Jun 25;3(6):118-121
pubmed: 30992903
J Hepatol. 2021 Sep;75(3):582-588
pubmed: 33887359
Clin Endocrinol (Oxf). 2018 Oct;89(4):408-413
pubmed: 29885255
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
J Hepatol. 2013 Apr;58(4):706-14
pubmed: 23238105
Bone Joint J. 2015 Mar;97-B(3):383-90
pubmed: 25737523
Liver Int. 2019 Oct;39(10):1937-1942
pubmed: 31152475
Hepatology. 2006 Apr;43(4):707-14
pubmed: 16557541
Hepatology. 2021 Jan;73(1):366-413
pubmed: 33219529
Ther Clin Risk Manag. 2014 Nov 18;10:937-48
pubmed: 25429224
Am J Gastroenterol. 2011 Mar;106(3):476-82
pubmed: 20978484
J Hepatol. 2016 Jan;64(1):179-202
pubmed: 26516032
J Gastroenterol Hepatol. 2019 Jun;34(6):1088-1092
pubmed: 30307066
Curr Gastroenterol Rep. 2020 Sep 17;22(12):56
pubmed: 32940785
Z Gastroenterol. 2021 Jan;59(1):43-49
pubmed: 33429449
J Hepatol. 2018 Sep;69(3):697-704
pubmed: 29673756